KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Charles River Laboratories International (CRL) Equity Average (2016 - 2025)

Charles River Laboratories International has reported Equity Average over the past 16 years, most recently at $3.3 billion for Q4 2025.

  • For Q4 2025, Equity Average fell 9.29% year-over-year to $3.3 billion; the TTM value through Dec 2025 reached $3.3 billion, down 9.29%, while the annual FY2025 figure was $3.3 billion, 6.12% down from the prior year.
  • Equity Average for Q4 2025 was $3.3 billion at Charles River Laboratories International, down from $3.4 billion in the prior quarter.
  • Over five years, Equity Average peaked at $3.8 billion in Q3 2024 and troughed at $2.2 billion in Q1 2021.
  • A 5-year average of $3.0 billion and a median of $3.2 billion in 2023 define the central range for Equity Average.
  • Biggest five-year swings in Equity Average: surged 32.21% in 2021 and later decreased 11.03% in 2025.
  • Year by year, Equity Average stood at $2.5 billion in 2021, then grew by 12.93% to $2.8 billion in 2022, then grew by 23.14% to $3.5 billion in 2023, then increased by 4.85% to $3.6 billion in 2024, then dropped by 9.29% to $3.3 billion in 2025.
  • Business Quant data shows Equity Average for CRL at $3.3 billion in Q4 2025, $3.4 billion in Q3 2025, and $3.3 billion in Q2 2025.